文献速递乳腺癌妇科肿瘤

BLM过表达促进DNA损伤并增加三阴性乳腺癌和浆液性卵巢癌对铂类药物的敏感性

Overexpression of BLM promotes DNA damage and increased sensitivity to platinum salts in triple-negative breast and serous ovarian cancers.
PubMed 文献 · Ann Oncol · 2018-01-01

该研究通过整合基因组学方法,在两组独立的新辅助顺铂治疗三阴性乳腺癌队列中对比敏感与耐药病例的基因表达和DNA拷贝数差异,发现BLM和FANCI基因拷贝数与表达均升高,且与卵巢癌铂类而非紫杉类反应相关;体外实验证实BLM过表达促进DNA损伤并诱导顺铂敏感性,但对紫杉醇敏感性无影响。

要点

  • BLM和FANCI基因拷贝数及表达升高与三阴性乳腺癌铂类敏感性相关。
  • BLM和FANCI表达升高与卵巢癌铂类反应相关,而与紫杉类反应无关。
  • BLM过表达促进DNA损伤并诱导顺铂敏感性,但不影响紫杉醇敏感性。

核心结论

  • 基于BLM和FANCI基因表达水平的生物标志物是预测三阴性乳腺癌和卵巢癌铂类敏感性的潜在指标。

研究设计与样本

  • 研究采用整合基因组学方法,在两组独立的新辅助顺铂治疗三阴性乳腺癌队列中对比敏感与耐药病例的基因表达和DNA拷贝数差异。
  • 通过体外过表达、敲低和靶向抑制剂处理研究显著差异基因的功能相关性。

主要发现

  • BLM和FANCI在两个铂类敏感病例中均显示DNA拷贝数和基因表达升高。
  • BLM和FANCI表达升高与卵巢癌铂类反应相关,但与紫杉类反应无关。
  • BLM过表达促进DNA损伤并诱导顺铂敏感性,对紫杉醇敏感性无影响。

临床怎么用

  • BLM和FANCI表达水平可作为预测三阴性乳腺癌和卵巢癌铂类敏感性的潜在生物标志物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Platinum-based therapy is an effective treatment for a subset of triple-negative breast cancer and ovarian cancer patients. In order to increase response rate and decrease unnecessary use, robust biomarkers that predict response to therapy are needed. PATIENTS AND METHODS: We performed an integrated genomic approach combining differential analysis of gene expression and DNA copy number in sensitive compared with resistant triple-negative breast cancers in two independent neoadjuvant cisplatin-treated cohorts. Functional relevance of significant hits was investigated in vitro by overexpression, knockdown and targeted inhibitor treatment. RESULTS: We identified two genes, the Bloom helicase (BLM) and Fanconi anemia complementation group I (FANCI), that have both increased DNA copy number and gene expression in the platinum-sensitive cases. Increased level of expression of these two genes was also associated with platinum but not with taxane response in ovarian cancer. As a functional validation, we found that overexpression of BLM promotes DNA damage and induces sensitivity to cisplatin but has no effect on paclitaxel sensitivity. CONCLUSIONS: A biomarker based on the expression levels of the BLM and FANCI genes is a potential predictor of platinum sensitivity in triple-negative breast cancer and ovarian cancer.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Birkbak NJ, Li Y, Pathania S, et al. Overexpression of BLM promotes DNA damage and increased sensitivity to platinum salts in triple-negative breast and serous ovarian cancers. Ann Oncol. 2018. PMID: 29452344. doi:10.1093/annonc/mdy049

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。